Gyre TherapeuticsGYRE +1.29%39 PB Ratio is 5.68 as of Jun. 27, 2026, which is 49% below its 10-year median of 11.17. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Gyre Therapeutics ranks worse than 73.94% on this metric.
Gyre Therapeutics Inc stock PB Ratio (=5.68) is close to 3-year low of 5.32.
The historical rank and industry rank for Gyre Therapeutics's PB Ratio or its related term are showing as below:
GYRE'
s PB Ratio Range Over the Past 10 Years
Min: 5.32 Med: 11.17 Max: 25.81
Current: 5.68
During the past 5 years, Gyre Therapeutics's highest PB Ratio was 25.81. The lowest was 5.32. And the median was 11.17.
GYRE's PB Ratio is ranked worse than 73.94% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs GYRE: 5.68
During the past 12 months, Gyre Therapeutics's average Book Value Per Share Growth Rate was 42.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 27.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Gyre Therapeutics was 27.90% per year. The lowest was -8.30% per year. And the median was 9.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Gyre Therapeutics PB Ratio Related Terms
Gyre Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Gyre Therapeutics (GYRE) has a PB Ratio of 5.68 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gyre Therapeutics and its competitors. This is 49% below median its historical median of 11.17. Over the past decade, Gyre Therapeutics' PB Ratio has ranged from 5.32 to 25.81. According to the industry distribution chart, Gyre Therapeutics ranks #911 out of 1232 companies in the Biotechnology industry, placing it in the top 73.9%.
Is Gyre Therapeutics' PB Ratio too high?
Gyre Therapeutics' current PB Ratio of 5.68 is 49% below median its 10-year median of 11.17. Over the past 10 years, this metric has ranged from a low of 5.32 to a high of 25.81. The Biotechnology industry median PB Ratio is 2.80. Gyre Therapeutics' value of 5.68 is 102.9% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #911 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' PB Ratio compare to CBIO and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #911 out of 1232 companies for PB Ratio. This places Gyre Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Gyre Therapeutics' value of 5.68 is 102.9% above this benchmark. Historically, Gyre Therapeutics' own PB Ratio has ranged from 5.32 to 25.81 over the past decade. While the company's 10-year median is 11.17 vs. the industry median of 2.80, Gyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current PB Ratio of 5.68 is 102.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current PB Ratio is 5.68, which is 49% below median its own 10-year median of 11.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.30 — trading 35.8% below its estimated fair value. The current PB Ratio is 5.68, which is 49% below median its 10-year median of 11.17 and 102.9% above the Biotechnology industry median of 2.80. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current PB Ratio is 5.68 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
PB Ratio: 5.68 (49% below median its 10-year median of 11.17)
GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
Industry Position: 102.9% above the Biotechnology median (#911 of 1232)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
